Offerings / Regulation CF / Frontier Bio Corporation

Frontier Bio Corporation

Regulation Crowdfunding offering on Wefunder · Form C filed March 5, 2026 · Hayward, California

SAFERevenue over $1MCorporation, DelawareHealthcareBiotechnology tissue engineering and lab-grown human tissue models

Frontier Bio Corporation, a Delaware corporation based in Hayward, California, develops lab-grown human tissue models sold to research and commercial customers and is developing a tissue-engineered vascular graft; it reports revenue of $1,394,414 for fiscal 2024 and 5 employees. The offering seeks a target of $50,000 and a maximum of $1,235,000 through Wefunder Portal LLC in SAFE securities, with the company operating since 2018.

Registry notesThe review report and Note 1 disclose substantial doubt about going concern, and the company reports net losses in both years, with 2024 net loss of $47,800 after a roughly $500,000 gain on sale of a related-party investment in Zeden Inc. The CEO holds approximately 35% of shares per Note 3 while Form C Item 6 reports 89.73% voting power, and Item 14/Item 10 and the Form C cover give inconsistent figures for prior year net loss and SAFE totals.

Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.

Offering terms

Security: Simple Agreement for Future Equity (SAFE)
Maximum: $1,235,000.00
Price: $1.00 per unit
Pricing method: Pro-rated portion of the total principal value of $50,000; interests will be sold in increments of $1; each investment is convertible to one share of stock as described under Item 13.
Deadline: April 30, 2026
Oversubscriptions: Accepted
Intermediary: Wefunder Portal LLC
Funding portal, SEC file 007-00033
Intermediary fee: 6.0% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
Intermediary equity: No
Co-issuer: Frontier Bio I, a series of Wefunder SPV, LLC
Frontier Bio I EB, a series of Wefunder SPV, LLC

Financials as filed

Item	Most recent FY	Prior FY
Revenue	$1,394,414	$1,317,864
Cost of goods sold	$832,110	$1,090,182
Net income (loss)	-$47,800	-$1,015,178
Total assets	$1,669,618	$1,606,435
Cash and equivalents	$832,040	$662,239
Accounts receivable	$2,022	$0
Short-term debt	$200,702	$808,325
Long-term debt	$189,747	$324,883
Taxes paid	$0	$0

Two fiscal years as reported on the Form C cover sheet. 5 employees. Offered in 56 states.

Use of proceeds

94% to legal, IP and operating expenses and 6% to Wefunder as intermediary fee, at both the $50,000 target and the $1,235,000 maximum. Filing states working capital and general corporate purposes with broad management discretion; Item 10 and the offering memorandum describe preclinical vascular graft work, customer acquisition and team and operations.

Valuation

SAFE with $24,000,000 valuation cap and 80% discount rate for general investors; $21,600,000 valuation cap and 80% discount for the first $200,000 of securities and Wefunder VIP investors (Terms Appendix states 20% discount). Price per interest stated as $1.00 with increments of $1.

Prior raises

Not stated

Financial statements

Financial statements for years ended December 31, 2024 and 2023 are unaudited and reviewed (not audited) by RNB Capital CPAs, LLC, with a review report dated February 11, 2026 that includes a going concern paragraph.